Key Viral Hepatitis Studies Influencing My Practice Following EASL 2022—Audio Recap
Listen to expert insights from Stefan Zeuzem, MD, on updates and new viral hepatitis data from EASL 2022, including novel therapeutics for HBV, HBV cure data, therapeutic updates for HDV, and HCV treatment for treatment-experienced patients.
Decera Clinical Education Infectious Disease Podcast · Stefan Zeuzem MD
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, Stefan Zeuzem, MD, discusses new viral hepatitis data from EASL 2022, including:
- Novel HBV therapeutics, including the REEF-2, B-Clear, and SAVE-1 studies
- HBV cure from the Everest Project in China
- HDV therapeutics from MYR301 and a study of bulevirtide in patients with cirrhosis and portal hypertension
- HCV retreatment in patients with prior direct-acting antiviral therapy failure
Presenter:
Stefan Zeuzem, MD
Professor of Medicine
Chief, Department of Medicine I
JW Goethe University Hospital
Frankfurt, Germany
Follow along with the downloadable slideset at:
https://bit.ly/3yJAruD
Link to full program:
https://bit.ly/3AjCNBC
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.